- Home
- NAAS vs AYTU Comparison
NAAS vs AYTU Comparison
Compare NAAS & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAAS
- AYTU
- Stock Information
- Founded
- NAAS 2019
- AYTU N/A
- Country
- NAAS China
- AYTU United States
- Employees
- NAAS N/A
- AYTU N/A
- Industry
- NAAS Other Specialty Stores
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- NAAS Consumer Discretionary
- AYTU Health Care
- Exchange
- NAAS Nasdaq
- AYTU Nasdaq
- Market Cap
- NAAS 8.3M
- AYTU 9.6M
- IPO Year
- NAAS 2017
- AYTU N/A
- Fundamental
- Price
- NAAS $0.85
- AYTU $2.10
- Analyst Decision
- NAAS
- AYTU
- Analyst Count
- NAAS 0
- AYTU 0
- Target Price
- NAAS N/A
- AYTU N/A
- AVG Volume (30 Days)
- NAAS 1.6M
- AYTU 624.8K
- Earning Date
- NAAS 07-23-2025
- AYTU 05-14-2025
- Dividend Yield
- NAAS N/A
- AYTU N/A
- EPS Growth
- NAAS N/A
- AYTU N/A
- EPS
- NAAS N/A
- AYTU N/A
- Revenue
- NAAS $43,258,393.00
- AYTU $81,659,000.00
- Revenue This Year
- NAAS $19.53
- AYTU N/A
- Revenue Next Year
- NAAS $151.36
- AYTU $8.68
- P/E Ratio
- NAAS N/A
- AYTU $11.39
- Revenue Growth
- NAAS 50.34
- AYTU 0.41
- 52 Week Low
- NAAS $0.60
- AYTU $0.95
- 52 Week High
- NAAS $41.80
- AYTU $2.96
- Technical
- Relative Strength Index (RSI)
- NAAS 33.62
- AYTU 60.77
- Support Level
- NAAS $0.60
- AYTU $1.97
- Resistance Level
- NAAS $0.96
- AYTU $2.17
- Average True Range (ATR)
- NAAS 0.14
- AYTU 0.14
- MACD
- NAAS -0.01
- AYTU 0.00
- Stochastic Oscillator
- NAAS 22.99
- AYTU 58.33
About NAAS NaaS Technology Inc.
Naas Technology Inc is an electric vehicle charging service provider in China, whose vision is to power the world with carbon-neutral energy. It offers an integrated set of online solutions to charging station operators. wide range of offline services that simplify the daily operations of charging station operators, and of non-charging services such as food and beverage services to station operators.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.